Collectively, these data suggest that TIM-3 blockade may also be effective in re-awakening T cell responses in cancer patients, including those with AML, particularly in combination with anti-PD-1 or anti-CTLA-4 therapy. The gene discussed is PDCD1; the disease is acute myeloid leukemia.